Study of Chronic Exposure of the Population Living on the Atlantic Coast and on the Caribbean Coast, in Martinique, During the Stranding Period and Outside the Stranding Period of Sargassum Seaweeds
NCT ID: NCT05564546
Last Updated: 2023-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
173 participants
INTERVENTIONAL
2022-08-18
2023-03-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Since 2011, massive strandings of Sargassum seaweed in the French West Indies are to be deplored. In recent years, strandings have increased. In Martinique, sargassum stranding occurs mainly on the Atlantic coast. The duration of stranding from one year to another is variable, but the period during which the stranding is maximum is between April and October.
The accumulation of strandings causes the compaction of algae and limits access to oxygen, which leads to anaerobic degradation which quickly results in the release of various gases, in particular hydrogen sulphide (H2S).
Acute H2S poisoning is well characterized clinically according to exposure (cutaneous, respiratory, ophthalmological, digestive, neurological symptoms, etc.). On the other hand, there are very few data available on the clinical effects of prolonged, repeated exposure and most often at low doses.
Among the toxic effects for which there are still uncertainties regarding long-term exposure to H2S are lung function, measured by spirometry, and airway inflammation, appreciable by measurement of FeNO (fractional exhaled nitric oxide).
The investigators consider it relevant to focus on the clinical and biological characteristics of the population exposed to sargassum in Martinique, in the field, assuming that exposure to sargassum H2S causes pulmonary effects measurable by spirometry and by FeNO, during the stranding period and outside this period.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
People exposed to sargassum seaweed stranding
Participant living on the Atlantic coast of Martinique island (hit by the strandings), close (less than 300 meters) to sargassum seaweed stranding areas: exposed group (85 subjects).
Participants will be examined directly at their place of residence.
Participants will be examinated two times:
* at Visit 1 - Day 0 during the strandings period,
* at Visit 2 - M+6 months (+/-1 month) after the end of the strandings.
FeNO (fractional exhaled nitric oxide)
FeNO measurement is a marker of airway inflammation. It is a non-invasive examination for the patient, easy to perform for healthcare personnel, the measurement of NO in exhaled air is one of the only non-invasive and reproducible examinations allowing the detection of inflammation airways.
The FeNO will be measured by an electrochemical NO analyzer of the NiOx Vero type (Circassia, The Surgical Company) and expressed in particles per billion (ppb). The objective and reproducible measurement of NO production by the bronchial mucosa is a reflection of the degree of airway inflammation. The measurement of exhaled NO is part of diagnostic health technologies aimed at quantifying airway inflammation, especially in asthmatic patients.
FeNO is considered normal for values of 16-25 ppb. A FeNO value \> 25 ppb will be a reason for consultation at the Martinique Hospital for additional assessment.
Spirometry
Spirometry tests will assess lung function. It is a safe and painless test to measure lung volumes and expiratory flows.
Ventilatory function is assessed by simple spirometry parameters such as forced expiratory volume in the first second (FEV1, in litres), vital capacity (CV, in litres), and the FEV1/CV ratio.
The results of the spirometry will be compared with the theoretical or predicted values calculated according to age, sex, height.The FEV1/CV ratio as a percentage is an indicator of the level of bronchial obstruction.
Spirometry is considered normal for CV values ≥80% and FEV1/FVC ≥0.70 of the predicted value. A value of CV \<80% or FEV \<80% of the predicted value will be a reason for consultation at the Martinique hospital for additional assessment.
Physical examination
A pulmonary clinical examination will be carried out by the investigator, including:
* Cough,
* Sputum,
* Vesicular murmur (MV),
* Added noises (BSA),
* Vocal vibrations (VV),
* Tympanism,
* Dullness,
* Signs of acute respiratory distress (ARD),
* …
Interrogation
Participants will undergo an interview with the medical team to collect the following information in particular:
Age, size, sex, medical history, smoking status, current treatments, potential symptoms, date of first symptoms, clinical manifestations experienced (respiratory, digestive, neurological, cardiac, psychiatric, visual, skin disorders, etc.) place of residence, concentration H2S in ppm on the site, presence of sand mist in the environment, etc.
People not exposed to sargassum seaweed stranding
Participant living on the Caribbean coast of Martinique island (not hit by the strandings): unexposed group (85 subjects).
Participants will be examined directly at their place of residence.
Participants will be examinated two times:
* at Visit 1 - Day 0 during the strandings period,
* at Visit 2 - M+6 months (+/-1 month) after the end of the strandings.
FeNO (fractional exhaled nitric oxide)
FeNO measurement is a marker of airway inflammation. It is a non-invasive examination for the patient, easy to perform for healthcare personnel, the measurement of NO in exhaled air is one of the only non-invasive and reproducible examinations allowing the detection of inflammation airways.
The FeNO will be measured by an electrochemical NO analyzer of the NiOx Vero type (Circassia, The Surgical Company) and expressed in particles per billion (ppb). The objective and reproducible measurement of NO production by the bronchial mucosa is a reflection of the degree of airway inflammation. The measurement of exhaled NO is part of diagnostic health technologies aimed at quantifying airway inflammation, especially in asthmatic patients.
FeNO is considered normal for values of 16-25 ppb. A FeNO value \> 25 ppb will be a reason for consultation at the Martinique Hospital for additional assessment.
Spirometry
Spirometry tests will assess lung function. It is a safe and painless test to measure lung volumes and expiratory flows.
Ventilatory function is assessed by simple spirometry parameters such as forced expiratory volume in the first second (FEV1, in litres), vital capacity (CV, in litres), and the FEV1/CV ratio.
The results of the spirometry will be compared with the theoretical or predicted values calculated according to age, sex, height.The FEV1/CV ratio as a percentage is an indicator of the level of bronchial obstruction.
Spirometry is considered normal for CV values ≥80% and FEV1/FVC ≥0.70 of the predicted value. A value of CV \<80% or FEV \<80% of the predicted value will be a reason for consultation at the Martinique hospital for additional assessment.
Physical examination
A pulmonary clinical examination will be carried out by the investigator, including:
* Cough,
* Sputum,
* Vesicular murmur (MV),
* Added noises (BSA),
* Vocal vibrations (VV),
* Tympanism,
* Dullness,
* Signs of acute respiratory distress (ARD),
* …
Interrogation
Participants will undergo an interview with the medical team to collect the following information in particular:
Age, size, sex, medical history, smoking status, current treatments, potential symptoms, date of first symptoms, clinical manifestations experienced (respiratory, digestive, neurological, cardiac, psychiatric, visual, skin disorders, etc.) place of residence, concentration H2S in ppm on the site, presence of sand mist in the environment, etc.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FeNO (fractional exhaled nitric oxide)
FeNO measurement is a marker of airway inflammation. It is a non-invasive examination for the patient, easy to perform for healthcare personnel, the measurement of NO in exhaled air is one of the only non-invasive and reproducible examinations allowing the detection of inflammation airways.
The FeNO will be measured by an electrochemical NO analyzer of the NiOx Vero type (Circassia, The Surgical Company) and expressed in particles per billion (ppb). The objective and reproducible measurement of NO production by the bronchial mucosa is a reflection of the degree of airway inflammation. The measurement of exhaled NO is part of diagnostic health technologies aimed at quantifying airway inflammation, especially in asthmatic patients.
FeNO is considered normal for values of 16-25 ppb. A FeNO value \> 25 ppb will be a reason for consultation at the Martinique Hospital for additional assessment.
Spirometry
Spirometry tests will assess lung function. It is a safe and painless test to measure lung volumes and expiratory flows.
Ventilatory function is assessed by simple spirometry parameters such as forced expiratory volume in the first second (FEV1, in litres), vital capacity (CV, in litres), and the FEV1/CV ratio.
The results of the spirometry will be compared with the theoretical or predicted values calculated according to age, sex, height.The FEV1/CV ratio as a percentage is an indicator of the level of bronchial obstruction.
Spirometry is considered normal for CV values ≥80% and FEV1/FVC ≥0.70 of the predicted value. A value of CV \<80% or FEV \<80% of the predicted value will be a reason for consultation at the Martinique hospital for additional assessment.
Physical examination
A pulmonary clinical examination will be carried out by the investigator, including:
* Cough,
* Sputum,
* Vesicular murmur (MV),
* Added noises (BSA),
* Vocal vibrations (VV),
* Tympanism,
* Dullness,
* Signs of acute respiratory distress (ARD),
* …
Interrogation
Participants will undergo an interview with the medical team to collect the following information in particular:
Age, size, sex, medical history, smoking status, current treatments, potential symptoms, date of first symptoms, clinical manifestations experienced (respiratory, digestive, neurological, cardiac, psychiatric, visual, skin disorders, etc.) place of residence, concentration H2S in ppm on the site, presence of sand mist in the environment, etc.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant living on the Atlantic coast in Martinique, close (less than 300 meters) to sargassum seaweed stranding areas (exposed group),
* Participant living on the Caribbean coast, in Martinique (unexposed group),
* Participant having been informed of the research,
* Participant having given his free, informed and express consent,
* Participant affiliated to a social security scheme.
Exclusion Criteria
* Participant with a known respiratory or cardiac pathology,
* Participant with a cognitive state that does not allow him to answer the questionnaire,
* Participant who refused to participate in the study,
* Pregnant or breastfeeding women.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Center of Martinique
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Center of Martinique
Fort-de-France, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A01382-41
Identifier Type: REGISTRY
Identifier Source: secondary_id
22_RIPH2-04
Identifier Type: -
Identifier Source: org_study_id